Pfizer and BioNTech abruptly halted a major U.S. trial for their updated COVID-19 booster in healthy adults aged 50-64 due to failed enrollment, reaching only a fraction of the intended 25,000–30,000 participants.
Public skepticism is surging, with only 18% of Americans opting for boosters (2025–2026 CDC data), as federal agencies push annual shots despite waning demand and FDA’s stricter trial requirements.
The FDA’s tougher stance – demanding placebo-controlled trials – reflects growing scrutiny over lack of long-term safety data and unclear benefits for low-risk groups, per agency officials like Dr. Vinay Prasad.
Moderna faces similar struggles, with its trial delayed until mid-2027, while neither Pfizer nor Moderna has full FDA approval for healthy adults under 65 – only emergency authorization for seniors/high-risk groups.
Collapse of mandates looms as pharmaceutical giants and agencies, once dismissive of hesitancy, now confront public refusal to comply – exposing unresolved safety concerns and profit-driven motives behind vaccine pushes.
Vaccine manufacturers Pfizer and BioNTech have abruptly halted a major U.S. trial testing their updated Wuhan coronavirus (COVID-19) vaccine booster in healthy adults aged 50 to 64, a move that underscores growing public skepticism toward the injections.
Read Full Article: https://www.naturalnews.com/2026-04-03-pfizer-biontech-end-covid19-vaccine-trial-us.html
